{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:41:55Z","timestamp":1793263315029,"version":"4.5.0"},"reference-count":23,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Congenital hyperinsulinism (CHI) is characterized by dysregulated insulin secretion causing hypoglycemia and consequent brain damage. Dasiglucagon is a glucagon analogue under investigation to treat CHI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of dasiglucagon delivered via continuous subcutaneous infusion to children with CHI and persistent hypoglycemia as add-on to standard of care (SoC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label trial, patients were randomized 1:1 to SoC or SoC + dasiglucagon (10-70\u2005\u00b5g\/h) for 4 weeks. In the following 4 weeks, all patients received dasiglucagon + SoC. Hypoglycemia was assessed by self-monitored plasma glucose (SMPG) and blinded continuous glucose monitoring (CGM). Primary endpoint was average number of SMPG-detected hypoglycemia episodes\/week (SMPG &amp;lt;3.9\u2005mmol\/L) during Weeks 2 to 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-two patients (0.6-10.9 years) were randomly assigned to dasiglucagon + SoC (n = 16) or SoC (n = 16). The rate of SMPG-detected hypoglycemia decreased from baseline in both groups, but with no statistically significant difference during Weeks 2 to 4 (event rate ratio: 0.85 [0.54; 1.36], P = .5028). However, dasiglucagon administration resulted in a 43% reduction in CGM-detected hypoglycemia (&amp;lt;3.9\u2005mmol\/L) vs SoC alone during Weeks 2 to 4 (post hoc analysis; event rate ratio: 0.57 [0.39; 0.83], P = .0029). Dasiglucagon enabled reductions (of 37% to 61%) in all other measures of hypoglycemia assessed by CGM vs SoC alone including extent and percent time in hypoglycemia (post hoc analyses). Dasiglucagon appeared safe and well tolerated. Skin and gastrointestinal events were more frequent with dasiglucagon + SoC than SoC only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinically meaningful reductions in all CGM-recorded measures of hypoglycemia support using dasiglucagon as a potential treatment for CHI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgad648","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:39:54Z","timestamp":1698752394000},"page":"1071-1079","source":"Crossref","is-referenced-by-count":14,"title":["Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children"],"prefix":"10.1210","volume":"109","author":[{"given":"Paul S","family":"Thornton","sequence":"first","affiliation":[{"name":"Congenital Hyperinsulinism Center, Cook Children\u2019s Medical Center , Fort Worth, TX 76104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1225-8087","authenticated-orcid":false,"given":"Diva D","family":"De Leon","sequence":"additional","affiliation":[{"name":"Congenital Hyperinsulinism Center, Division of Endocrinology and Diabetes, Children\u2019s Hospital of Philadelphia , Philadelphia, PA 19104 , USA"},{"name":"Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania , Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Empting","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Otto-von-Guericke University , Magdeburg 39120 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9575-9436","authenticated-orcid":false,"given":"David","family":"Zangen","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem , Jerusalem 91240 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Kendall","sequence":"additional","affiliation":[{"name":"Research and Development, Zealand Pharma A\/S , S\u00f8borg 2860 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sune","family":"Birch","sequence":"additional","affiliation":[{"name":"Research and Development, Zealand Pharma A\/S , S\u00f8borg 2860 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"B\u00f8ge","sequence":"additional","affiliation":[{"name":"Research and Development, Zealand Pharma A\/S , S\u00f8borg 2860 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Ivkovic","sequence":"additional","affiliation":[{"name":"Research and Development, Zealand Pharma A\/S , S\u00f8borg 2860 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4280-7470","authenticated-orcid":false,"given":"Indraneel","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology, Royal Manchester Children's Hospital , Manchester M13 9WL , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"issue":"1","key":"2024031503433171200_dgad648-B1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-022-02214-y","article-title":"Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families","volume":"17","author":"Banerjee","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2024031503433171200_dgad648-B2","doi-asserted-by":"crossref","first-page":"e0228417","DOI":"10.1371\/journal.pone.0228417","article-title":"Using referral rates for genetic testing to determine the incidence of a rare disease: the minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389","volume":"15","author":"Yau","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"2024031503433171200_dgad648-B3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1750-1172-6-63","article-title":"Congenital hyperinsulinism: current trends in diagnosis and therapy","volume":"6","author":"Arnoux","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"2024031503433171200_dgad648-B4","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2015-2539","article-title":"High risk of diabetes and neurobehavioral deficits in individuals with surgically treated hyperinsulinism","volume":"100","author":"Lord","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024031503433171200_dgad648-B5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40272-019-00334-w","article-title":"Current and emerging agents for the treatment of hypoglycemia in patients with congenital hyperinsulinism","volume":"21","author":"De Cosio","year":"2019","journal-title":"Paediatr Drugs"},{"issue":"5","key":"2024031503433171200_dgad648-B6","doi-asserted-by":"crossref","first-page":"e98054","DOI":"10.1371\/journal.pone.0098054","article-title":"Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism","volume":"9","author":"Arya","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"2024031503433171200_dgad648-B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1530\/eje.0.1490043","article-title":"Long-term follow-up of 114 patients with congenital hyperinsulinism","volume":"149","author":"Meissner","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2024031503433171200_dgad648-B8","doi-asserted-by":"crossref","first-page":"E1786","DOI":"10.1210\/jc.2013-2094","article-title":"Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases","volume":"98","author":"Lord","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2024031503433171200_dgad648-B9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/8904_2018_140","article-title":"The effect of continuous intravenous glucagon on glucose requirements in infants with congenital hyperinsulinism","volume":"45","author":"Hawkes","year":"2018","journal-title":"JIMD Rep"},{"key":"2024031503433171200_dgad648-B10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fendo.2020.00441","article-title":"Efficacy of dose-titrated glucagon infusions in the management of congenital hyperinsulinism: A case series","volume":"11","author":"Salomon-Estebanez","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2024031503433171200_dgad648-B11","first-page":"94","article-title":"Effect of glucagon on glucose production, lipolysis, and gluconeogenesis in familial hyperinsulinism","volume":"50","author":"Cederblad","year":"1998","journal-title":"Horm Res"},{"issue":"10","key":"2024031503433171200_dgad648-B12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/archpedi.156.10.999","article-title":"Experience with intravenous glucagon infusions as a treatment for resistant neonatal hypoglycemia","volume":"156","author":"Miralles","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"2024031503433171200_dgad648-B13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/pedi.12453","article-title":"Congenital hypoglycemia disorders: new aspects of etiology, diagnosis, treatment and outcomes: highlights of the proceedings of the congenital hypoglycemia disorders symposium, Philadelphia April 2016","volume":"18","author":"De Leon","year":"2017","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"2024031503433171200_dgad648-B14","first-page":"59","article-title":"Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon","volume":"70","author":"Mohnike","year":"2008","journal-title":"Horm Res"},{"key":"2024031503433171200_dgad648-B15"},{"issue":"3","key":"2024031503433171200_dgad648-B16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dc17-1402","article-title":"Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog","volume":"41","author":"H\u00f6velmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"suppl 2","key":"2024031503433171200_dgad648-B17","first-page":"61","article-title":"Dasiglucagon significantly reduces requirement for intravenous glucose in children with congenital hyperinsulinism ages 7 days to 12 months","volume":"95","author":"De Leon","year":"2022","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2024031503433171200_dgad648-B18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024031503433171200_dgad648-B19","unstructured":"Thornton PS, De Leon DD, Empting S, et al Supplementary materials. Figshare. Deposited on 8 November, 2023. https:\/\/doi.org\/10.6084\/m9.figshare.24518920"},{"issue":"12","key":"2024031503433171200_dgad648-B20","doi-asserted-by":"crossref","first-page":"e21770","DOI":"10.2196\/21770","article-title":"Open-Source technology for real-time continuous glucose monitoring in the neonatal intensive care unit: case study in a neonate with transient congenital hyperinsulinism","volume":"22","author":"Braune","year":"2020","journal-title":"J Med Internet Res"},{"issue":"10","key":"2024031503433171200_dgad648-B21","doi-asserted-by":"crossref","first-page":"e26957","DOI":"10.2196\/26957","article-title":"Clustering of hypoglycemia events in patients with hyperinsulinism: extension of the digital phenotype through retrospective data analysis","volume":"23","author":"Worth","year":"2021","journal-title":"J Med Internet Res"},{"issue":"5","key":"2024031503433171200_dgad648-B22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00000441-200105000-00003","article-title":"The glucagonoma syndrome: a review of its features and discussion of new perspectives","volume":"321","author":"Chastain","year":"2001","journal-title":"Am J Med Sci"},{"issue":"1","key":"2024031503433171200_dgad648-B23","first-page":"1","article-title":"An ongoing phase 2 study of HM15126, a novel long-acting analogue, in subjects with congental hyperinsulinism (ACHIEVE)","volume":"95","author":"Shin","year":"2022","journal-title":"Horm Res Paediatr"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad648\/53401448\/dgad648.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/4\/1071\/56950115\/dgad648.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/4\/1071\/56950115\/dgad648.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T23:44:23Z","timestamp":1710459863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/4\/1071\/7335551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2024,3,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad648","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,11,1]]}}}